Last reviewed · How we verify
NCT07004257: ButOx
ButOx Human Trial: An Open Label Prospective Cohort Study to Investigate the Effect of Tributyrin (Butyrate Precursor Molecule) Supplementation on Markers of Calcium Oxalate Nephrolithiasis
NA trial testing tributyrin in Urolithiasis in 10 participants. Not yet recruiting.
1 July 2027
Quick facts
| Lead sponsor | University of British Columbia |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 10 |
| Start date | 1 July 2025 |
| Primary completion | 1 July 2027 |
| Estimated completion | 1 July 2028 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- tributyrin — full drug profile →
Conditions studied
- Urolithiasis — all drugs for Urolithiasis →
Sponsor
University of British Columbia
Who can join
19 and older, any sex, with Urolithiasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Kidney stone disease (KSD) is a condition where there are crystal deposits in the kidney. The gut microbiome is a community of gut bacteria which can produce substances such as short chain fatty acids (SCFAs). Individuals with KSD have a different gut microbiome composition and lower amounts of these SCFAs compared to healthy individuals. Tributyrin is a supplement which can increase levels of SCFAs. Our data from animal studies indicate that tributyrin supplementation may be able to reduce kidney stone formation. This pilot clinical trial will test if tributyrin supplementation helps in prevention or treatment of those with KSD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07004257
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of tributyrin
Trials testing the same drug.
- NCT06797817 — Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain · Phase 3 · not yet recruiting
- NCT07503548 — Effect of Tributyrin Supplementation on Glycemic Control, Inflammation, and Cardiovascular Risk in Patients With Type 2 · Phase 3 · not yet recruiting
- NCT05446168 — Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation · Phase 1 · terminated
Other recruiting trials for Urolithiasis
Currently open trials in the same condition.
- NCT07378904 — Sterile Water Injection vs Morphine for Renal Colic · NA · active not recruiting
- NCT06989320 — Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease · NA · recruiting
- NCT06651294 — Efficacy of Neorenal Forte for the Complete Elimination of Residual Fragments · NA · recruiting
- NCT07514676 — Predictive Value of Preoperative Urine Culture for Postoperative Fever After FANS-RIRS When Surgery Proceeds Before Cult · active not recruiting
- NCT06158620 — Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease · Phase 1, PHASE2 · recruiting
Other University of British Columbia trials
Trials by the same sponsor.
- NCT07340970 — Sensory Stimuli During Cesarean Delivery · not yet recruiting
- NCT07481201 — Phenylalanine Requirements in the Menstrual Phases · NA · not yet recruiting
- NCT07492095 — Leucine Requirements in School-Age Children · NA · not yet recruiting
- NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI · NA · recruiting
- NCT07519928 — Exploring the Feasibility and Benefits of Implementing Pelvic Floor Muscle Training During Inpatient Rehabilitation for · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07004257 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of British Columbia
- Last refreshed: 4 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07004257.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing